noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Kirkland & Ellis LLP

Private Equity/M&A Partner Adam Prince Joins Kirkland & Ellis
Oakland University

Natalie Ishioka named Student of the Year by the Great Lakes Affiliate[...]
ImmuCell Corporation

2025 Form 10-K (proofs 0000811641 118730 ALL DOCS clean pn120)

Healthcare

Pappas Capital LLC

07/23/2013 | Press release | Archived content

TYRX Receives FDA Clearance for AIGISRx® Neuro Antibacterial Enve...

News | 07. 23. 2013

TYRX

Expands Access to Proven Antibacterial Technology to Neurosurgery

Monmouth Junction, NJ. (July 23, 2013): TYRX, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market the AIGISRx Antibacterial Envelope for use with vagus nerve stimulators, which are currently used to treat seizure disorders and depression. This approval extends TYRX's leadership in the
commercialization of implantable medical devices designed to help reduce surgical-site infections (SSIs) associated with implantable devices into the field of neurosurgery.

Pappas Capital LLC published this content on July 23, 2013, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:03 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format